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Tracking nitroxyl-derived posttranslational
modifications of phospholamban in cardiac myocytes
Cecilia Beatriz Mundiña-Weilenmann and Alicia Mattiazzi
Cardiovascular disease is the leading cause of morbidity and
mortality worldwide. Calcium (Ca2+) mishandling is one of the
most striking abnormalities in this wide spectrum of patholo-
gies, among which heart failure (HF) remains the leading cause
of death in developed countries (Benjamin et al., 2018). A hall-
mark of HF in both human and animal models is impaired Ca2+
sequestration into the SR, which contributes to the decreased
contractile performance in this disease (Gwathmey et al., 1987;
Meyer et al., 1995; del Monte et al., 2002). Not surprisingly, this
defective mechanism has been targeted with novel therapeutic
strategies that are now undergoing experimental and clinical
testing in animals and patients (Pfeffer et al., 2015; Hulot et al.,
2016, 2017; Motloch et al., 2018). In this issue of JGP, Keceli et al.
provide novel insights into the molecular mechanism from
which nitroxyl (HNO), nitric oxide (NO)’s one-electron-reduced
and protonated sibling, recently emerged as a promising can-
didate for HF treatment.
Overview of excitation–contraction coupling
In normal hearts, Ca2+ enters the cell through voltage-dependent
Ca2+ channels (L-type Ca2+ channels) and subsequently binds to
and activates the SR Ca2+ release channels or ryanodine receptor
2 (RYR2) to trigger further Ca2+ release. (Fig. 1) This process,
known as CICR (Fabiato and Fabiato, 1977), essentially amplifies
the Ca2+ signal, increasing cytosolic Ca2+ to produce contraction
at the myofilament level. Relaxation occurs when cytosolic Ca2+
returns to basal diastolic values. The majority of this task is
accomplished by SERCA2a, which mediates Ca2+ uptake into the
SR, and to a lesser extent by the Na+/Ca2+ exchanger (NCX),
which normally transfers Ca2+ to the extracellular space in ex-
change for entry of Na+ (Bers, 2001).
Regulation of SR Ca2+ uptake by phospholamban
The activity of SERCA2a is reversibly regulated by phospho-
lamban (PLN), a 52–amino acid protein (Tada et al., 1975) lo-
calized to the longitudinal SR (Jorgensen and Jones, 1987).
Sequence analysis of PLN has shown that the protein is orga-
nized into three domains: two cytosolic domains (Ia and Ib) and
a transmembrane domain (II; Simmerman and Jones, 1998).
Domain Ia contains Ser16 and Thr17, the sites of phosphorylation
by PKA and CaMKII, respectively (Wegener et al., 1989). It is
well known that dephosphorylated PLN binds to the trans-
membrane domains of SERCA2a (Kimura et al., 1996) and allo-
sterically inhibits SR Ca2+ reuptake (MacLennan and Kranias,
2003). Conversely, phosphorylation of PLN relieves SERCA2a
inhibition, increasing the affinity of the enzyme for Ca2+ and
enhancing the rates of SR Ca2+ uptake and myocardial relaxa-
tion. This in turn leads to an increased SR Ca2+ load, SR Ca2+
release, and contractility (Lindemann et al., 1983; Lindemann
and Watanabe, 1985; Mundiña-Weilenmann et al., 1996).
Experimental evidence suggests two possible mechanistic
models by which PLN phosphorylation releases its inhibitory
action. In one, phosphorylation results in the physical dissocia-
tion of PLN from SERCA2a (Chen et al., 2007). In the other,
phosphorylation shifts the cytoplasmic domain of PLN toward a
noninhibitory conformational state, leaving the transmembrane
domain anchored to the Ca2+ pump (Gustavsson et al., 2013).
Another point to consider is the dynamic equilibrium that exists
between monomeric and pentameric forms of PLN in SR
membranes, which is also influenced by the phosphorylation
status of the protein (Simmerman and Jones, 1998). Although
evidence supports the assertion that the monomer is the active
species of PLN (MacLennan and Kranias, 2003), x-ray crystal-
lography studies indicate that SERCA2a also interacts with
pentameric PLN, pointing to a potential role of this oligomeric
form in regulating SERCA2a activity (Stokes et al., 2006; Glaves
et al., 2011).
New insights on SERCA2a regulation: PLN partners and redox
modifications. The emergence of HNO
The classical view of SERCA2a regulation by PLN phosphoryla-
tion was modified and enriched by further investigations. These
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revealed that PLN does not act alone but in association with a set
of proteins that regulate SR Ca2+ uptake: the PLN/SERCA2a in-
teractome (for reviews, see Haghighi et al., 2014; Mattiazzi and
Kranias, 2014). Moreover, it became clear that PLN is also reg-
ulated by posttranslational modifications that are different from
phosphorylation and evoked by reactive oxygen and nitrogen
species (ROS and RNS, respectively; Bigelow and Squier, 2005;
Froehlich et al., 2008; Lancel et al., 2009; Ha et al., 2011;
Sivakumaran et al., 2013; Irie et al., 2015). Among the RNS is
HNO, the one-electron reduction product of NO. HNO avidly
reacts with nucleophiles, especially thiols, to yield either disul-
fides or sulfinamides; a redox change exclusive to HNO. Fur-
thermore, the hydrophobic nature of HNO makes it more likely
to react with thiols in hydrophobic regions. Thus, HNO reac-
tivity toward thiol-containing proteins is different from its redox
sibling NO and other recognized oxidizing agents. Intriguingly,
the putative physiological relevance of HNO, as well as the pos-
sibility of an endogenous source in biological systems, has been
difficult to establish, owing to its short-lived characteristics.
However, the emergence of HNO donors as ideal pharmacological
agents in the treatment of HF (Paolocci et al., 2001, 2003; also see
below), has recently gained considerable interest.
Cardiac effects of HNO
HNOwas initially identified as a vasorelaxant agent (for review,
see Bullen et al., 2011). Later on, its importance as a positive
inotropic and lusitropic agent was recognized in seminal
works by Paolocci et al. (2001, 2003), performed in conscious
instrumented dogs with normal or failing hearts. The effects
were independent of the cardiac loading conditions (e.g., alter-
ations in pre- and afterload) as well as of β-adrenergic signaling
(Paolocci et al., 2003). These novel findings signaled the onset of
a new era of scientific research that raised the significance of
HNO from an almost overlooked agent to a potential candidate
for HF treatment (Hasenfuss and Teerlink, 2011). Further work
demonstrated that the effects resulted from a direct action of
HNO on SERCA2a and RYR2, leading to increased SR Ca2+ uptake
and release. These HNO cardiac effects were fully reversible and
independent of both cAMP/PKA and cGMP/PKG signaling.
Additional results indicated that PLN plays a central role in
the HNO enhancement of SERCA2a activity. When the three
cysteines (Cys) of PLN transmembrane domainwere replaced by
alanine, the stimulatory action of HNO was lost (Froehlich et al.,
2008). Similar to one of the suggested mechanisms for how PLN
phosphorylation reduces SERCA2a inhibition (Gustavsson et al.,
2013, and see above), it was proposed that HNO functionally
uncouples PLN from SERCA without altering the physical as-
sociation between both proteins (Sivakumaran et al., 2013).
New mechanistic insights into the effects of HNO
Keceli et al. (2019) extend these previous results by adding
significant insight into the mechanism by which HNO affects SR
Ca2+ uptake. By using 15N-edited NMR spectroscopy (a technique
that allows detection of sulfinamides, redox changes on thiols
that are unique to HNO) in concert with measurements of
SERCA2a activity and immunoblots, the authors were able to
Figure 1. Schematic depicting excitation−contraction coupling and the mechanism of HNO action. The main HNO targets in cardiac myocytes are shown
as well as the proposed mechanism by which HNO modifies SERCA2a/PLN interaction. Upon membrane depolarization, Ca2+ (yellow spheres) enters the cell
through L-type Ca2+ channels (LTCC) and activates the RYR2 of the SR to produce further Ca2+ release. Ca2+ binds to the myofilaments (MF) to produce
contraction. Most of the Ca2+ is then reuptaken by SERCA2a, and a small fraction is extruded from the cell through NCX. HNO activates RYR2 and SR Ca2+
release, SR Ca2+ uptake, and MF Ca2+ sensitivity, without significantly affecting LTCC and NCX. The inset of the figure shows the mechanism proposed by Keceli
et al. (2019) by which HNO modifies thiol groups in PLN. It is suggested that when the HNO/thiol stoichiometry approaches a 1:1 ratio, similar to that an-
ticipated in vivo under normal physiological conditions, an intramolecular disulfide bond between two cysteines of the transmembrane domain of PLN is
formed, relieving the preexisting SERCA2a inhibition.
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address two important remaining questions regarding the
mechanisms by which HNO modifies PLN function and SR Ca2+
sequestration. Specifically, they discovered that Cys41 and Cys46
are the main targets of HNO that functionally uncouple PLN
from SERCA2a and activate SR Ca2+ pump. In addition, they
found that when the HNO:thiol ratio approaches values similar
to those expected in vivo in cardiac cells, intramolecular disul-
fide bond formation between Cys41 and Cys46 in PLN monomer
predominates over irreversible sulfinamide links (Fig. 1). This is
important because, unlike sulfinamide formation, reduction of
disulfide bonds can be completed within a few minutes at
physiological pH and temperature. These results match the fast
reversibility of HNO-induced effects previously observed
in vitro and in vivo (Paolocci et al., 2001, 2003; Froehlich et al.,
2008; Sivakumaran et al., 2013), strongly suggesting that the
physiological effects of HNO donors on the cardiac system are
likely due to the formation of reversible disulfide linkages rather
than sulfinamides. These latter results constitute an important
clue for the potential role of HNO as a signaling molecule in the
cardiovascular system. In addition, the results reinforce previous
findings, which indicate that the HNO signaling and contractile
effects are different from the more traditional β1/β2 agonists.
Perspectives
Collectively, the results of Keceli et al. (2019) deepen under-
standing of the mechanism by which HNO increases SR Ca2+
uptake at the molecular level and provide new insights into
the reactive redox switches of PLN. Several questions still
remain, however. For instance, as the authors recognize, new
accurate detection methods are needed to know where and
how much HNO is produced in vivo. Moreover, it is not clear
whether HNO-induced enhancement of SR Ca2+ uptake also
involves direct effects on SERCA2a. Keceli et al. (2019) present
evidence supporting the idea that PLN is the main HNO target.
Indeed, they accurately show that mutation of Cys41 and
Cys46 of PLN to alanine reduces the HNO-induced enhance-
ment of SERCA2a activity. In contrast, prior results from
Lancel et al. (2009) indicated that HNO-induced increases in
SR Ca2+ uptake are due to direct SERCA2a activation, inde-
pendently of PLN, via S-glutathiolation at Cys674. An alter-
native explanation to these somewhat controversial results is
that the action of HNO on PLN and SERCA might represent
complementary or even redundant mechanisms (assuming
that HNO is a physiological signaling molecule), which con-
tribute similarly at the intact myocyte level.
The novel mechanistic insights presented by Keceli et al.
(2019) also provide new support for the use of HNO donors in
HF treatment. In this scenario, the diversity of actions evoked by
HNO on excitation–contraction coupling proteins different from
PLN and SERCA2a deserves comment (Fig. 1). It has been shown
that HNO does not significantly affect L-type Ca2+ current (Kohr
et al., 2010), but increases myofilament Ca2+ sensitivity, which
would add to the potency of HNO as an inotropic agent and favor
its beneficial effect on HF (Gao et al., 2012). It has also been
shown that HNO enhances RYR2 activity (Tocchetti et al., 2007).
This effect occurs in association with increased SR Ca2+ uptake,
increased fractional Ca2+ release, and no change in SR Ca2+ load.
Although these results emphasize the value of HNO donors as
innovative pharmacological tools to enhance myocardial Ca2+
cycling, an important concern not yet clarified is their potential
arrhythmogenicity. An increase in SR Ca2+ uptake that would
potentially increase (or maintain) SR Ca2+ load and an en-
hancement in RYR2 activity (Tocchetti et al., 2007; Keceli et al.,
2019) are two conditions that favor arrhythmogenic SR Ca2+ leak
(Zima et al., 2014). Importantly, an increase in SR Ca2+ sparks
has been observed in “healthy” myocytes in the presence of the
HNO donor (Tocchetti et al., 2007). An excess of SR Ca2+ sparks
may produce Ca2+ waves that propagate through cardiac cells.
Spontaneous Ca2+ waves are arrhythmogenic because, by acti-
vating inwardmembrane currents (mainly the electrogenic NCX
working in the forward mode), they depolarize the cell mem-
brane and eventually produce an ectopic beat (Pogwizd and
Bers, 2004; Laurita a nd Rosenbaum, 2008). Considering that
HF myocytes often have a leaky RYR2 and are prone to pro-
arrhythmic events (Belevych et al., 2011; Zima et al., 2014), it
is still uncertain whether the beneficial effects on contractility
produced by HNO donors could be compromised in nonhealthy
myocytes by a possible arrhythmogenic effect. The work of
Keceli et al. (2019) and previous work from the same group
(Froehlich et al., 2008; Tocchetti, 2007; Sivakumaran et al.,
2013), provides valuable mechanistic insight into the role of
HNO on SR Ca2+ uptake at the molecular level. Similar mecha-
nistic studies on the effect of HNO on SR Ca2+ release will be
most welcome in the near future to provide a better under-
standing of the effects of HNO donors on HF.
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